围手术期持续抗凝治疗对机器人辅助根治性前列腺切除术后出血结局的影响
该回顾性研究纳入2014年1月至2020年1月接受机器人辅助根治性前列腺切除术的606例前列腺癌患者,其中31例围手术期持续使用抗凝药物。与继续使用氯吡格雷/普拉格雷、单用阿司匹林及无抗血栓药物的患者相比,抗凝组在需输血、额外干预或再入院的出血并发症、血栓并发症、估计失血量及总体并发症方面均无显著差异。结论认为围手术期持续抗凝在该类手术中可行。
要点
- 抗凝组仅1例(3%)需术后输血,无额外干预或再入院。
- 抗凝组与其他组在出血、血栓及总体并发症上无显著差异。
- 围手术期持续使用抗凝药物在机器人辅助根治性前列腺切除术中可行。
核心结论
- 围手术期持续抗凝治疗对机器人辅助根治性前列腺切除术患者是可行的。
研究设计与样本
- 回顾性研究,2014年1月至2020年1月共620例前列腺癌患者接受机器人辅助根治性前列腺切除术,排除14例停用抗血栓治疗者,最终纳入606例。
- 抗凝组31例,噻吩吡啶组13例,阿司匹林组61例,对照组501例。
主要发现
- 抗凝组31例中,20例(65%)使用直接口服抗凝药,11例(35%)使用华法林,5例联用阿司匹林。
- 抗凝组仅1例(3%)需术后输血,无额外干预或再入院。
临床怎么用
- 对于接受机器人辅助根治性前列腺切除术的患者,围手术期持续使用抗凝药物可能不需常规中断,但需个体化评估出血与血栓风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the impact of continued perioperative anticoagulant drug administration on bleeding and complications in patients undergoing robot-assisted radical prostatectomy. METHODS: Between January 2014 and January 2020, 620 patients with prostate cancer underwent robot-assisted radical prostatectomies and were retrospectively reviewed. Fourteen patients who discontinued antithrombotic therapy were excluded. Among the 606 included patients, 31 continued anticoagulant therapy during the perioperative phase (anticoagulant group). The anticoagulant group outcomes were compared with those of patients who continued clopidogrel and prasugrel (thienopyridine group = 13), aspirin monotherapy (aspirin group = 61), and no chronic antithrombotic agent (control group = 501). The primary outcome was the incidence of bleeding complications requiring transfusion, additional intervention, or readmission. Secondary outcomes were the incidence of thrombotic complications, estimated blood loss, and overall complication rates. RESULTS: Among the 31 patients in the anticoagulant group, 20 (65%) used directed oral anticoagulants, 11 (35%) used warfarin, and 5 used combined aspirin. Only 1 (3%) patient in the anticoagulant group required postoperative transfusion, and none required additional interventions or readmission. No significant differences were detected between the anticoagulant and other groups (anticoagulant vs thienopyridine, aspirin, and control groups) regarding bleeding complications (3% vs 8%, P = .51; 0%, P = .34; 0.4%, P = .17, respectively), thrombotic complications (3% vs 0%, P = .70; 2%, P = .56; 0.2%, P = .11, respectively), estimated blood loss (200 vs 100 mL, P = .63; 175 mL, P = .64; 165 mL, P = .74, respectively), or other high-grade complications (6% vs 0%, P = .49; 2%, P = .26; 3%, P = .24, respectively). CONCLUSION: Perioperative continuation of anticoagulant use is feasible for patients undergoing robot-assisted radical prostatectomy.
引用
- Kubota M, Matsuoka T, Yamasaki T, et al. Effect of Continued Perioperative Anticoagulant Therapy on Bleeding Outcomes Following Robot-assisted Radical Prostatectomy. Urology. 2020. PMID: 33248139. doi:10.1016/j.urology.2020.08.095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。